Navitor Pharmaceuticals, Inc., a Cambridge, MA-based biopharmaceutical company developing novel medicines by targeting cellular nutrient signaling, raised $23.5m Series A financing.
Backers included Polaris Partners, Atlas Venture, Johnson & Johnson Development Corporation, SR One and The Longevity Fund.
The company intends to use the funds to advance its proprietary drug discovery platform and accelerate the development of a pipeline of novel drugs.
Led by Alan Crane, Founder and Chairman of Navitor and a Partner at Polaris Partners, scientific founder, David M. Sabatini, MD, PhD, Professor of Biology at MIT, Member of the Whitehead Institute for Biomedical Research, and Investigator at Howard Hughes Medical Institute, George P. Vlasuk, PhD, President and Chief Executive Officer, Navitor has developed a proprietary drug discovery platform and novel drugs that target cellular nutrient signaling via the mTORC1 pathway to address a wide range of diseases, including metabolic, neurodegenerative, autoimmune and musculoskeletal diseases, as well as several rare disorders.
The company has exclusive access from the Whitehead Institute to fundamental intellectual property from Dr. Sabatini’s laboratory relating to nutrient sensing via the mTORC1 pathway for use in pharmaceutical and other applications.